Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2020’, provides an overview of the Onychomycosis (Tinea Unguium) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium)

– The report reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Onychomycosis (Tinea Unguium) therapeutics and enlists all their major and minor projects

– The report assesses Onychomycosis (Tinea Unguium) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Onychomycosis (Tinea Unguium)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acea Biotech Inc

Almirall SA

Ascil Proyectos SL

Blueberry Therapeutics Ltd

CSA Biotechnologies LLC

DermBiont Inc

Exodos Life Sciences Limited Partnership

Hallux Inc

Hexima Ltd

Kaken Pharmaceutical Co Ltd

Meiji Seika Pharma Co Ltd

Moberg Pharma AB

Mycovia Pharmaceuticals Inc

NAL Pharmaceuticals Ltd

Novabiotics Ltd

Novan Inc

Photonamic GmbH & Co KG

Sanotize Research And Development Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Onychomycosis (Tinea Unguium) - Overview

Onychomycosis (Tinea Unguium) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Onychomycosis (Tinea Unguium) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development

Acea Biotech Inc

Almirall SA

Ascil Proyectos SL

Blueberry Therapeutics Ltd

CSA Biotechnologies LLC

DermBiont Inc

Exodos Life Sciences Limited Partnership

Hallux Inc

Hexima Ltd

Kaken Pharmaceutical Co Ltd

Meiji Seika Pharma Co Ltd

Moberg Pharma AB

Mycovia Pharmaceuticals Inc

NAL Pharmaceuticals Ltd

Novabiotics Ltd

Novan Inc

Photonamic GmbH & Co KG

Sanotize Research And Development Corp

Onychomycosis (Tinea Unguium) - Drug Profiles

aminolevulinic acid hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Onychomycosis (Tinea Unguium) - Dormant Projects

Onychomycosis (Tinea Unguium) - Product Development Milestones

Featured News & Press Releases

Appendix

List of Tables

List of Tables

Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Onychomycosis (Tinea Unguium) – Pipeline by Acea Biotech Inc, H1 2020

Onychomycosis (Tinea Unguium) – Pipeline by Almirall SA, H1 2020

Onychomycosis (Tinea Unguium) – Pipeline by Ascil Proyectos SL, H1 2020

Onychomycosis (Tinea Unguium) – Pipeline by Blueberry Therapeutics Ltd, H1 2020

Onychomycosis (Tinea Unguium) – Pipeline by CSA Biotechnologies LLC, H1 2020

Onychomycosis (Tinea Unguium) – Pipeline by DermBiont Inc, H1 2020

Onychomycosis (Tinea Unguium) – Pipeline by Exodos Life Sciences Limited Partnership, H1 2020

Onychomycosis (Tinea Unguium) – Pipeline by Hallux Inc, H1 2020

Onychomycosis (Tinea Unguium) – Pipeline by Hexima Ltd, H1 2020

Onychomycosis (Tinea Unguium) – Pipeline by Kaken Pharmaceutical Co Ltd, H1 2020

Onychomycosis (Tinea Unguium) – Pipeline by Meiji Seika Pharma Co Ltd, H1 2020

Onychomycosis (Tinea Unguium) – Pipeline by Moberg Pharma AB, H1 2020

Onychomycosis (Tinea Unguium) – Pipeline by Mycovia Pharmaceuticals Inc, H1 2020

Onychomycosis (Tinea Unguium) – Pipeline by NAL Pharmaceuticals Ltd, H1 2020

Onychomycosis (Tinea Unguium) – Pipeline by Novabiotics Ltd, H1 2020

Onychomycosis (Tinea Unguium) – Pipeline by Novan Inc, H1 2020

Onychomycosis (Tinea Unguium) – Pipeline by Photonamic GmbH & Co KG, H1 2020

Onychomycosis (Tinea Unguium) – Pipeline by Sanotize Research And Development Corp, H1 2020

Onychomycosis (Tinea Unguium) – Dormant Projects, H1 2020

Onychomycosis (Tinea Unguium) – Dormant Projects, H1 2020 (Contd..1), H1 2020

List of Figures

List of Figures

Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports